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license (http://creativecommons.org/Abstract Transcatheter aortic valve implantation (TAVI) was introduced as an alternative
treatment for patients with severe symptomatic aortic stenosis for whom surgery would be
high-risk. Prosthetic aortic valve endocarditis is a serious complication of surgical AVR (SAVR)
with high morbidity and mortality. According to recent cases, post-TAVI prosthetic valve endo-
carditis (PVE) seems to occur very rarely. We present the case of a 75-year-old woman who un-
derwent TAVI (Edwards Saphien XT) with an uneventful postoperative stay. She was diagnosed
with endocarditis using three dimensional (3D) echocardiography on the TAVI device 7 months
later and she subsequently underwent surgical aortic valve replacement. Little experience of
the interpretation of transoesophageal echocardiography (TEE) and the clinical course and
effectiveness of treatment strategies in post-TAVI endocarditis exists. We report a case of
PVE in a TAVI patient which was diagnosed with three-dimensional transoesophageal echocar-
diography (3DTEE).
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Transcatheter aortic valve implantation (TAVI) has evolved
into an alternative to surgical aortic valve replacement
(SAVR) for patients with high or prohibitive surgical risks
who have severe aortic stenosis.1 Since transcatheter aortic
valve replacement (TAVR) was first successfully performed
in 2002, the number of patients treated continues to
exponentially increase. Recent advances in the available
TAVI devices may make “complex” procedures feasible.2
In addition to significant comorbidities, TAVI patients are
typically frail and have impaired mobility. These factors
may render them more prone to infections, including
endocarditis. However, experience with transcatheter
prosthetic valve endocarditis (TPVE) remains limited, and
the current guidelines do not include any specific provisions
for TPVE.3,4
In this case presentation, we discuss the potentially
growing problem of complications related to transcatheter
valve implantation.
2. Case report
A 75-year-old woman with a significant history of RCA ste-
nosis and symptomatic severe aortic stenosis presented to
the emergency department with angina and New York Heart
Association Class IV dyspnoea. She had been previously
refused for conventional aortic valve replacement due to
her high-risk profile. The patient’s estimated operative risk
was significantly high due to multiple comorbidities that
included advanced age, atrial fibrillation, arterial hyper-
tension, pulmonary hypertension and coronary artery
disease.
A transthoracic echocardiogram (TTE) revealed severe
aortic stenosis (mean gradient: 49 mmHg; AVA: 0.9 cm2),
mild aortic and mitral regurgitation, and an ejection frac-
tion (EF) of 50% and pulmonary hypertension (pulmonary
artery systolic pressure: 37 mm/Hg) were also noted. The
aortic annulus diameter was measured at 21 mm with TEE.Figure 1 Increased aorticThe possibility of operative mortality was calculated to
be 11.5% according to the scoring of the Society of Thoracic
Surgeons (STS). Our institutional ‘Heart Team’ voted for
TAVI, and she underwent an initially uneventful trans-
femoral implantation of a 26-mm Sapien XT (Edwards
Lifesciences, Irvine, CA) aortic bioprosthesis.
Prophylactic antibiotics and anticoagulation medication
were administered before and during the procedure. First-
generation cephalosporin was chosen as a prophylactic and
administered during the hospital stay and until 1 week after
discharge.
The TAVI procedure was applied in a catheterization
laboratory under general anaesthesia with TEE guidance.
Percutaneous access was achieved and closure was per-
formed with a Prostar XL (ProStar  XL10Fr, Abbott
Vascular, Abbott Park, IL, USA) device. After the aortic
valve was crossed, valvuloplasty at a pace of 200/min was
performed using a 20-mm x 40-mm balloon, and a 26-mm
Edwards e Saphien XT valve was then implanted. No addi-
tional complications were observed.
The transthoracic echocardiography was repeated after
the procedure. A mild paravalvular leak was present, and
the functions of the implanted aortic valve were good
(average gradient: 11 mmHg). The pulmonary artery sys-
tolic pressure (PASP) was 25 mmHg. The TAVR was associ-
ated with a decrease in the PASP.
The patient was discharged on the 10th day following the
procedure. The follow-up TTEs, which were performed at 1
month, 3 months and 6 months after discharge, revealed no
changes in aortic valve function.
The patient was readmitted to our institution at seven
months due to acute congestive heart failure and palpita-
tion. Her body temperature was normal (36.8C), the white
blood cell count (WBC) was 7.2/ml, the C reactive protein
(CRP) level was elevated (12.2 mg/dl), and there was no
peripheral stigma of infective endocarditis or embolic
phenomena. An increased aortic valve gradient (mean
gradient: 37 mmHg) and mild aortic regurgitation were
observed on TTE (Fig. 1). The pulmonary artery systolic
pressure (PASP) was 40 mmHg. Two-dimensional TEE hasvalve gradient on TTE.
Figure 2 2D TEE image displaying the oscillating structure (10*7 mm) on the right coronary cusp of the aortic valve that was
suggestive of vegetation during systole and diastole. Arrow pointing right: vegetation (Veg), Ao: aorta, LV: left ventricle.
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3D TEE revealed a large, accessory, oscillating structure
(10*7 mm) on the right coronary cusp of the aortic valve
that was suggestive of vegetation (Figs. 2,3, and 4). Six
blood cultures were immediately taken, and two were
positive for Enterococcus faecium. The patient was tested
for antimicrobial susceptibility to select the optimal ther-
apy. Treatment with i.v. antibiotics (i.e., gentamycin,
ampicillin/sulbactam and rifampicin) was initiated. After
one week of antibiotherapy, control TEEs (2D-3D) were
performed and revealed no reduction in the vegetation and
no decrease in the aortic valve mean gradient.Figure 3 2D transoesophageal echocardiogram from the mid-
oesophageal AV short axis view. Arrow pointing right: aortic
valve (AV), arrow pointing left: vegetation (Veg), TV: tricuspid
valve, RV: right ventricle, RA: right atrium, PA: pulmonary ar-
tery, LA: left atrium.Our heart team made the decision for surgery because
the patient did not respond to the antibiotherapy and
exhibited continuous hemodynamic instability. Cardiopul-
monary bypass was established in a standard fashion. Car-
diac arrest was obtained with antegrade and retrograde
cardioplegia. Vegetation was observed on the TAVI valve
and resected (Fig. 5). A 21-mm Edwards bioprosthetic valve
was reimplanted. The cardiopulmonary bypass was termi-
nated uneventfully with inotropic support. However, on the
first postoperative day, haemodynamic instability,
including rhythm disturbances, occurred and necessitated
intra-aortic balloon pump insertion. Nevertheless, the pa-
tient died despite all the supportive and surgical
management.
3. Discussion
Aortic valve sclerosis is present in 20e30% of individuals
over 65 years and 48% of those aged 85 years or older.5
Twenty-five to thirty-five percent of those with severe
aortic stenosis who require SAVR cannot be operated on.6
Transcatheter aortic valve replacement is a novel proce-
dure that is used for patients with severe symptomatic
aortic stenosis and a high surgical risk.
Infectious prosthetic valve endocarditis is known as a
catastrophic complication that occurs in 0.3e1% of patients
following SAVR,7 and the in-hospital mortality reaches 30%.
Although TAVI is generally a relatively safe procedure,
heart teams must be prepared to tackle potential obsta-
cles.8 The lifelong prevalence of infective endocarditis (IE)
is approximately 10% to 15% across all cases, and the
morbidity and mortality rates are high.9,10
The microorganisms that are most commonly responsible
for infective endocarditis are coagulase-negative staphy-
lococci (52%), enterococci (8%), Streptococcus viridans
Figure 4 Assessment of the aortic prosthesis vegetation with the help of three-dimensional (3D) transoesophageal echocardi-
ography (TEE).
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cases of prosthetic valve endocarditis and S. viridans, S.
aureus, Staphyloccocus epidermidis and Enteroccoci in
cases of native valve endocarditis.11
The recommendations regarding PVE diagnosis and
management are well established12; however, no such in-
formation is available regarding transcatheter aortic valve
replacement infective endocarditis (TAVRIE). The definitive
incidence of TAVRIE is unclear because this condition has
currently been reported in only a few case reports.13,14 In
the PARTNER trial,15 which is the largest randomised trial
that has compared TAVI and SAVR in high-risk patients, the
incidence of endocarditis was reported; the incidences of
prosthesis infections at 30 days (0 in the TAVI patients and
one in the surgical cohort) and one year (2 (1.1%) in the
TAVI group) were low compared with the 3 surgically
implanted valve infections.1
Little is known about the microbiological profile of
TAVRIE. Staphylococcus aureus is the leading cause of both
early and late onset surgical PVE. The ‘‘typical’’ microor-
ganisms that are responsible for TAVRIE are not necessarily
identical to those that are responsible for SAVR. Only one ofFigure 5 Image of the resected TAVI valve.the reported cases of IE after TAVR was due to Staphylo-
coccus aureus, which is the most common pathogen in IE
after SAVR. The microbiological profile of TAVRIE may be
different from the surgical counterpart. Enterococci are
the predominant species in the normal flora found on the
skin of the groin and are intrinsically resistant to
cephalosporins.
The Duke criteria remain the gold standard for the
diagnosis of IE in patients who have undergone TAVR, and
exact criteria and definitions have yet to be established.
The relatively new 3DTEE technology allows for detailed
3D assessments of the cardiac structures.16,17 Real-time 3D
transoesophageal echocardiography (3DTEE) has the po-
tential to provide 3D information about intracardiac masses
and will provide important advances in the knowledge of
infective endocarditis in the future. 3DTEE is an important
tool for fine-tuning a suspected diagnosis for both medical
and surgical decision making when 2D echocardiography is
not completely clear.
It is important to diagnose IE early and provide prompt
and definitive treatment.7 The treatment of choice for IE
after TAVR cannot be dictated according to conventional
guidelines, and until further data are available, case-by-
case decisions based on clinical judgment or confirmed in-
fectious diagnoses should be undertaken. Larger series and
longer follow-ups must be reported to determine the fre-
quency of this complication, the microorganisms that are
responsible for it, and its appropriate treatment.
Cases of IE are managed either conservatively with an-
tibiotics and/or surgery, and the overall prognosis is poor.
Enterococcal PVE is often complicated by periprosthetic
dehiscence, annular abscesses or fistulas. In these cases, if
antibiotic treatment fails, an early surgical intervention
should be considered. Until further evidence is presented,
IE after TAVR should be managed according to SAVR
guidelines with modifications as needed on a case-by-case
basis. While surgical intervention can be life-saving even in
elderly patients with SPVE, it may not be a feasible treat-
ment option for the majority of TPVE patients.18
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conditions during TAVI are crucial, but the choice of pro-
phylactic antibiotics may influence the prevalence of
pathogens and the timing of infection. This supposition has
not been evaluated in the TAVR literature. Antibiotic pro-
phylaxis suitable for sternotomy may not be the best choice
for the transfemoral approach. There may be concerns that
a non-surgical environment might imply less stringent hy-
gienic and sterile precautions and thereby increase the risk
of procedure-related and prosthetic infections, especially
in this highly vulnerable patient group.3
In conclusion, TAVI candidates are probably at higher
risk for all postoperative complications due to their
comorbidities and advanced age, which should remind us
that these patients are at very high risk for redo SAVR.
Moreover, this report emphasized the importance of real-
time 3DTEE in suspected TAVRIE cases when 2D echocardi-
ography is not completely clear because real-time 3DTEE
might add prognostic information for decision-making.References
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